Stockreport

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oruka Therapeutics, Inc.  (ORKA) 
PDF ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides [Read more]